ArticleOncology letters2012
Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding.Cancer letters · 2025Review
- Lipid metabolic reprogramming and associated ferroptosis in osteosarcoma: From molecular mechanisms to potential targets.Journal of bone oncology · 2025Review
- SPICE1 promotes osteosarcoma growth by enhancing the deubiquitination of FASN mediated by USP10.Journal of translational medicine · 2025Article
- Targeting tumor angiogenesis and metabolism: a new perspective in pediatric thoracic tumor therapy.Frontiers in cell and developmental biology · 2025Review
- Osteosarcoma immunometabolism: emerging mechanisms and clinical implications.Frontiers in immunology · 2025Review
- Ubiquitination in lipid metabolism reprogramming: implications for pediatric solid tumors.Frontiers in immunology · 2025Review
- Metabolic reprogramming in osteosarcoma.Pediatric discovery · 2023Review
- Article
- Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma.Oncology letters · 2021Article
- Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming.Frontiers in oncology · 2021Review
- Article
- Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma.Cell death & disease · 2019Article
- Progress in the chemotherapeutic treatment of osteosarcoma.Oncology letters · 2018Review
- Blocking fatty acid synthase inhibits tumor progression of human osteosarcoma by regulating the human epidermal growth factor receptor 2/phosphoinositide 3-kinase/protein kinase B signaling pathway in xenograft models.Experimental and therapeutic medicine · 2017Article
- Transcription factor NF‑YA promotes a malignant phenotype by upregulating fatty acid synthase expression.Molecular medicine reports · 2016Article
- Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.Oncotarget · 2015Article
- MicroRNA-142-3p, a novel target of tumor suppressor menin, inhibits osteosarcoma cell proliferation by down-regulation of FASN.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Up-regulated FASN expression promotes transcoelomic metastasis of ovarian cancer cell through epithelial-mesenchymal transition.International journal of molecular sciences · 2014Article
- MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Interaction between fatty acid synthase and human epidermal growth receptor 2 (HER2) in osteosarcoma cells.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous experimental evidence has suggested that fatty acid synthase (FASN) may be involved in cancer metastasis. However, its role has been poorly evaluated in osteosarcoma. The aim of this study was to investigate the correlation of FASN expression with pulmonary metastasis and the correlation of FASN expression with the Ki-67 antigen, a proliferation marker, in patients with osteosarcoma of the extremities. The expression of FASN protein and Ki-67 was detected by immunohistochemistry of biopsy tissues from 136 patients with osteosarcoma of the extremities and 21 cases of osteoenchondroma. Positive expression of the FASN protein was observed and located in the cytoplasm. The positive expression rate of FASN was 63.2% in osteosarcoma and 28.6% in osteoenchondroma (p<0.05). The expression levels of the FASN protein were higher in the cases with lung metastasis compared to those without metastasis (p<0.01). The percentage of Ki-67 stained nuclei in osteosarcoma with pulmonary metastasis and in those without was 43.43±10.05 and 25.41±6.68%, respectively (p<0.01). There was a positive correlation between FASN and Ki-67 protein expression in osteosarcoma (Spearman's rho, F=43.05, R=0.734). Therefore, FASN may be a promising target in the treatment of osteosarcoma metastasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.